PortalPublikationenPharmakologische Langzeitbehandlung schizophrener Erkrankung...

Pharmakologische Langzeitbehandlung schizophrener Erkrankungen

Standard

Pharmakologische Langzeitbehandlung schizophrener Erkrankungen. / Deutschenbaur, L; Lambert, M; Walter, M; Naber, D; Huber, C G.

in: NERVENARZT, Jahrgang 85, Nr. 3, 01.03.2014, S. 363-375.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Deutschenbaur, L, Lambert, M, Walter, M, Naber, D & Huber, CG 2014, 'Pharmakologische Langzeitbehandlung schizophrener Erkrankungen', NERVENARZT, Jg. 85, Nr. 3, S. 363-375. https://doi.org/10.1007/s00115-013-3807-7

APA

Deutschenbaur, L., Lambert, M., Walter, M., Naber, D., & Huber, C. G. (2014). Pharmakologische Langzeitbehandlung schizophrener Erkrankungen. NERVENARZT, 85(3), 363-375. https://doi.org/10.1007/s00115-013-3807-7

Vancouver

Deutschenbaur L, Lambert M, Walter M, Naber D, Huber CG. Pharmakologische Langzeitbehandlung schizophrener Erkrankungen. NERVENARZT. 2014 Mär 1;85(3):363-375. https://doi.org/10.1007/s00115-013-3807-7

Bibtex

@article{0b64ce16585e445391cd176a2571132d,
title = "Pharmakologische Langzeitbehandlung schizophrener Erkrankungen",
abstract = "Schizophrenia spectrum disorders (SSD) constitute a group of psychiatric illnesses which frequently lead to persisting mental impairment. Although some patients show a clinical course with few episodes and good long-term outcome, the course of the disease is often chronic and unfavorable. Long-term treatment (LTT) of SSD pertains to the postacute stabilization period and the remission period following pharmacological and psychosocial therapy of an acute illness episode. This article provides an overview of treatment recommendations concerning long-term pharmacotherapy, dealing with side effects, treatment of non-response and therapy resistance and the treatment of psychiatric comorbidities. Furthermore, an overview of non-pharmacological treatment options is presented. An integrated therapeutic setting combining evidence-based pharmacotherapy, psychosocial interventions, and supportive therapies is recommended for optimal LTT of SSD. Considering the limited financial resources available in the healthcare system, one of the major challenges is to provide patients with access to the evidence-based treatment options available.",
keywords = "Antipsychotic Agents, Cognitive Therapy, Combined Modality Therapy, Dose-Response Relationship, Drug, Evidence-Based Medicine, Humans, Schizophrenia, Schizophrenic Psychology, Treatment Outcome",
author = "L Deutschenbaur and M Lambert and M Walter and D Naber and Huber, {C G}",
year = "2014",
month = mar,
day = "1",
doi = "10.1007/s00115-013-3807-7",
language = "Deutsch",
volume = "85",
pages = "363--375",
journal = "NERVENARZT",
issn = "0028-2804",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - Pharmakologische Langzeitbehandlung schizophrener Erkrankungen

AU - Deutschenbaur, L

AU - Lambert, M

AU - Walter, M

AU - Naber, D

AU - Huber, C G

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Schizophrenia spectrum disorders (SSD) constitute a group of psychiatric illnesses which frequently lead to persisting mental impairment. Although some patients show a clinical course with few episodes and good long-term outcome, the course of the disease is often chronic and unfavorable. Long-term treatment (LTT) of SSD pertains to the postacute stabilization period and the remission period following pharmacological and psychosocial therapy of an acute illness episode. This article provides an overview of treatment recommendations concerning long-term pharmacotherapy, dealing with side effects, treatment of non-response and therapy resistance and the treatment of psychiatric comorbidities. Furthermore, an overview of non-pharmacological treatment options is presented. An integrated therapeutic setting combining evidence-based pharmacotherapy, psychosocial interventions, and supportive therapies is recommended for optimal LTT of SSD. Considering the limited financial resources available in the healthcare system, one of the major challenges is to provide patients with access to the evidence-based treatment options available.

AB - Schizophrenia spectrum disorders (SSD) constitute a group of psychiatric illnesses which frequently lead to persisting mental impairment. Although some patients show a clinical course with few episodes and good long-term outcome, the course of the disease is often chronic and unfavorable. Long-term treatment (LTT) of SSD pertains to the postacute stabilization period and the remission period following pharmacological and psychosocial therapy of an acute illness episode. This article provides an overview of treatment recommendations concerning long-term pharmacotherapy, dealing with side effects, treatment of non-response and therapy resistance and the treatment of psychiatric comorbidities. Furthermore, an overview of non-pharmacological treatment options is presented. An integrated therapeutic setting combining evidence-based pharmacotherapy, psychosocial interventions, and supportive therapies is recommended for optimal LTT of SSD. Considering the limited financial resources available in the healthcare system, one of the major challenges is to provide patients with access to the evidence-based treatment options available.

KW - Antipsychotic Agents

KW - Cognitive Therapy

KW - Combined Modality Therapy

KW - Dose-Response Relationship, Drug

KW - Evidence-Based Medicine

KW - Humans

KW - Schizophrenia

KW - Schizophrenic Psychology

KW - Treatment Outcome

U2 - 10.1007/s00115-013-3807-7

DO - 10.1007/s00115-013-3807-7

M3 - SCORING: Zeitschriftenaufsatz

C2 - 24603949

VL - 85

SP - 363

EP - 375

JO - NERVENARZT

JF - NERVENARZT

SN - 0028-2804

IS - 3

ER -